Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 01, 2026 18:02 ET | Source: Mesoblast Limited

Mesoblast Announces Changes to Board of Directors' Leadership Roles

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed...
December 29, 2025 18:57 ET | Source: Mesoblast Limited

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE...
December 11, 2025 18:22 ET | Source: Mesoblast Limited

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent...
December 03, 2025 18:10 ET | Source: Mesoblast Limited

Mesoblast Participation at Piper Sandler Conference

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at...
November 24, 2025 18:39 ET | Source: Mesoblast Limited

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update,...
November 20, 2025 18:32 ET | Source: Mesoblast Limited

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high...
November 17, 2025 01:52 ET | Source: Mesoblast Limited

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection...
November 04, 2025 18:40 ET | Source: Mesoblast Limited

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food...
October 19, 2025 19:48 ET | Source: Mesoblast Limited

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...
October 06, 2025 19:24 ET | Source: Mesoblast Limited

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of...